文献速递头颈与中枢神经肿瘤

SPECTA-AYA研究中青少年和年轻成人高级别胶质瘤的分子分析:特征认识不足且常见胚系改变的肿瘤

Molecular analysis of adolescent and young adult high grade gliomas in the SPECTA-AYA study: Poorly characterised tumours with frequent germline alterations.
PubMed 文献 · Eur J Cancer · 2025-05-13

研究前瞻性纳入50例12-29岁新诊断或复发高级别胶质瘤及其他高危中枢神经系统肿瘤患者,行全外显子测序、RNA测序和甲基化谱分析及中心病理复核。分子与病理复核使相当比例患者组织学分级重新分类、诊断细化或修正;14%存在致病性体质性改变,91%的高级别胶质瘤有潜在可靶向改变,10例治疗根据分子谱修改。

要点

  • 分子与病理复核使46例局部诊断高级别胶质瘤中相当比例患者组织学分级重新分类、诊断细化或修正。
  • 91%的高级别胶质瘤存在潜在可靶向改变,涉及RAS/RAF/MAPK、PI3K/AKT/mTOR和细胞周期基因。
  • 14%总体存在致病性体质性改变,主要限于IDH野生型胶质母细胞瘤和儿童型弥漫性高级别胶质瘤。

核心结论

  • 青少年和年轻成人高级别胶质瘤包含多样化的实体;准确的分子定义诊断对于指导初始治疗、确定遗传易感性风险和指导分子靶向治疗至关重要。
  • 当前服务未能常规解决这一高危、预后差的罕见癌症患者群体的诊断、个性化分子谱分析或治疗机会探究。

研究设计与样本

  • 前瞻性招募50例12-29岁新诊断或复发高级别胶质瘤及其他高危中枢神经系统肿瘤患者至EORTC SPECTA平台研究。
  • 所有患者接受全外显子测序、RNA测序和甲基化谱分析,并进行中心病理复核;报告可操作突变并随访治疗和结局。

主要发现

  • 从46例局部诊断高级别胶质瘤和4例其他复发中枢神经系统肿瘤中,分子与病理复核导致组织学分级重新分类(n=10)、诊断细化(n=9)和诊断修正(n=12),占相当比例。
  • 总体14%存在致病性体质性改变,主要限于IDH野生型胶质母细胞瘤和儿童型弥漫性高级别胶质瘤病例。
  • 91%的高级别胶质瘤具有潜在可靶向改变,影响RAS/RAF/MAPK(60%)、PI3K/AKT/mTOR(27%)和细胞周期基因(11%)。
  • 高肿瘤突变负荷(>10个体细胞非同义突变/Mb靶向基因组)在诊断时见于12%、复发时见于18%,均为组织学4级肿瘤。
  • 10例患者的治疗根据分子谱修改,其中5例在末次随访时仍在治疗中。

关键数值与推荐

  • 致病性体质性改变总体检出率为14%。
  • 高级别胶质瘤中潜在可靶向改变的总检出率为91%,其中RAS/RAF/MAPK占60%、PI3K/AKT/mTOR占27%、细胞周期基因占11%。
  • 高肿瘤突变负荷定义为>10个体细胞非同义突变/Mb靶向基因组,诊断时检出率12%、复发时18%,均为组织学4级肿瘤。

临床怎么用

  • 作者认为青少年和年轻成人高级别胶质瘤的准确分子定义诊断对指导初始治疗、确定遗传易感性风险和指导分子靶向治疗至关重要。
  • 作者指出当前服务未能常规解决这一高危、预后差的罕见癌症患者群体的诊断、个性化分子谱分析或治疗机会探究。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adolescent and young adult (AYA) high grade gliomas (HGG) have the worst survival of AYA malignancies yet are poorly represented in large-scale molecular datasets. METHODS: 50 AYAs aged 12-29 with newly diagnosed or recurrent HGG and other high risk central nervous system (CNS) tumours were prospectively recruited to the EORTC SPECTA platform study and underwent whole exome sequencing, RNA sequencing and methylation profiling, with central pathological review. Actionable mutations were reported and patients followed up for therapies and outcome. RESULTS: From 46 locally diagnosed HGGs and 4 other recurrent CNS tumours, molecular and pathology review resulted in histological grade re-classification (n = 10), diagnostic refinement (n = 9) and revised diagnoses (n = 12) in a substantial proportion. Pathogenic constitutional alterations were present in 14 % overall and were largely limited to cases with IDH-wildtype glioblastoma and paediatric-type diffuse HGGs. 91 % of HGGs had potentially actionable alterations affecting RAS/RAF/MAPK (60 %), PI3K/AKT/mTOR (27 %) and cell cycle genes (11 %). High tumour mutational burden (> 10 somatic non-synonymous mutations per Mb of genome targeted) was present in 12 % at diagnosis and 18 % at recurrence, all in histological grade 4 tumours. Ten patients' treatment was modified on the basis of molecular profile, of whom 5 remained on treatment at last follow-up. CONCLUSION: AYA HGGs comprise a diverse group of entities; accurate, molecularly-defined diagnosis is critical to direct primary treatment, determine risk of genetic predisposition and guide molecularly-directed therapy. Current services fail to routinely address diagnosis, personalised molecular profiling or investigation of therapeutic opportunities for this high risk, poor prognosis group of rare cancer patients.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Morfouace M, Bielle F, Razis E, et al. Molecular analysis of adolescent and young adult high grade gliomas in the SPECTA-AYA study: Poorly characterised tumours with frequent germline alterations. Eur J Cancer. 2025. PMID: 40393126. doi:10.1016/j.ejca.2025.115493

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。